Concepedia

Author

W. Jonat

Christian-Albrechts-Universität zu Kiel

Also Known As

Aman U. Buzdar, Jonat, Walter, K Otto, Köchli, Ossi, Köchli, Ossi R, Omer Gunal, W Jonat, W. JONAT, W. Jonat, Walter Jonat

621

Publications

16.4K

Citations

59

H-Index

153

Concepts

All Affiliations

Christian-Albrechts-Universität zu KielUniversity of LübeckUniversity Hospital Schleswig-HolsteinUniversität HamburgCharité - Universitätsmedizin Berlin
WJ

About

W. Jonat is an author at Christian-Albrechts-Universität zu Kiel specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

45

106

7.3K

2

Health Sciences

11

13

1.1K

3

Public Health

7

7

178

4

Engineering

2

2

122

5

Education

1

1

166

W. Jonat

×

166

Publications

13.9K

Citations

54

H-Index

YearCitations

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, S. M. Steinberg, M Blichert-Toft,

PubMed

1998

2.2K

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

R. Jakesz, W. Jonat, Michael Gnant,

The Lancet

2005

871

Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

Manfred Kaufmann, Gabriel N. Hortobágyi, Aron Goldhirsch,

Journal of Clinical Oncology

2006

718

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

José Baselga, Peter van Dam, Alexey Manikhas,

Journal of Clinical Oncology

2009

658

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata,

The Lancet Oncology

2017

532

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

Aman U. Buzdar, W. Jonat, Anthony Howell,

PubMed

1998

418

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

A. U. Buzdar, W. Jonat, Anthony Howell,

Journal of Clinical Oncology

1996

410

Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study

W. Jonat, M. Kaufmann, Willi Sauerbrei,

Journal of Clinical Oncology

2002

335

Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study

Manfred Kaufmann, W. Jonat, J. Hilfrich,

Journal of Clinical Oncology

2007

269

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *

W. Jonat, Anthony Howell, Carl Blomqvist,

European Journal of Cancer

1996

255

Page 1